Xcout Intel
Zag Bio
Zag Bio is a biotechnology research company headquartered in Cambridge, Massachusetts. The enterprise focuses on developing innovative therapies for autoimmune diseases by targeting the thymus gland to engage the body's natural T cell central tolerance mechanisms.
Subscribe to see Zag Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Zag Bio at a glance
Zag Bio is a biotechnology company headquartered in United States. Its most recent funding round, Series A, raised $80M in October 2025. Xcout tracks 11 named people at Zag Bio, including Jason Cole (CEO).
Zag Bio leadership
- Jason ColeCEO
- Jason F. ColeChief Executive Officer and Board Member
- Alison ConlonChief Operating Officer
- Jan HillsonChief Medical Officer
- John KulmanChief Scientific Officer
- John D. KulmanChief Scientific Officer and Co-Founder
5 more named people on record for Zag Bio, with roles, board committees and tenure — see the full roster →
Zag Bio funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $80M | 12 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Zag Bio competitors
A few of Zag Bio's closest competitors — see the full list of competitors and alternatives →
Oblenio Bio is a biotechnology research company headquartered in Lexington, Massachusetts, focused on transforming the treatment of refractory autoimmune diseases by delivering a broad immune system reset.
TECregen AG is a biotechnology company headquartered in Basel, Switzerland. The company is dedicated to advancing immuno-rejuvenation through the development of next-generation therapies designed to regenerate the thymus.
Ethyreal Bio is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing precision therapies for thyroid diseases with high unmet medical needs.
TRex Bio, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on discovering and developing precision therapeutics to treat moderate-to-severe immune-mediated diseases by targeting regulatory T cells.
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Get Zag Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Zag Bio in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access